| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 6341 | 2020 |
| Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1836, 2020 | 2703 | 2020 |
| Autoantibodies against type I IFNs in patients with life-threatening COVID-19 P Bastard, LB Rosen, Q Zhang, E Michailidis, HH Hoffmann, Y Zhang, ... Science 370 (6515), eabd4585, 2020 | 2672 | 2020 |
| Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore BE Young, SWX Ong, S Kalimuddin, JG Low, SY Tan, J Loh, OT Ng, ... Jama 323 (15), 1488-1494, 2020 | 2593 | 2020 |
| Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ... Science 370 (6515), eabd4570, 2020 | 2294 | 2020 |
| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1889 | 2021 |
| Remdesivir for 5 or 10 days in patients with severe Covid-19 JD Goldman, DCB Lye, DS Hui, KM Marks, R Bruno, R Montejano, ... New England Journal of Medicine 383 (19), 1827-1837, 2020 | 1695 | 2020 |
| Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial CD Spinner, RL Gottlieb, GJ Criner, JRA López, AM Cattelan, ... Jama 324 (11), 1048-1057, 2020 | 1538 | 2020 |
| A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction CW Tan, WN Chia, X Qin, P Liu, MIC Chen, C Tiu, Z Hu, VCW Chen, ... Nature biotechnology 38 (9), 1073-1078, 2020 | 1238 | 2020 |
| Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail J Hansen, A Baum, KE Pascal, V Russo, S Giordano, E Wloga, BO Fulton, ... Science 369 (6506), 1010-1014, 2020 | 1031 | 2020 |
| Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients PY Chia, KK Coleman, YK Tan, SWX Ong, M Gum, SK Lau, XF Lim, ... Nature communications 11 (1), 2800, 2020 | 972 | 2020 |
| Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures R Pung, CJ Chiew, BE Young, S Chin, MIC Chen, HE Clapham, AR Cook, ... The Lancet 395 (10229), 1039-1046, 2020 | 807 | 2020 |
| Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients AT Tan, M Linster, CW Tan, N Le Bert, WN Chia, K Kunasegaran, ... Cell reports 34 (6), 2021 | 710 | 2021 |
| Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a … PNA Harris, PA Tambyah, DC Lye, Y Mo, TH Lee, M Yilmaz, TH Alenazi, ... Jama 320 (10), 984-994, 2018 | 679 | 2018 |
| Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey A Versporten, P Zarb, I Caniaux, MF Gros, N Drapier, M Miller, V Jarlier, ... The Lancet Global Health 6 (6), e619-e629, 2018 | 646 | 2018 |
| Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients IYJ Seah, DE Anderson, AEZ Kang, L Wang, P Rao, BE Young, DC Lye, ... Ophthalmology 127 (7), 977-979, 2020 | 544 | 2020 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 513 | 2021 |
| Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study BE Young, SW Fong, YH Chan, TM Mak, LW Ang, DE Anderson, CYP Lee, ... The lancet 396 (10251), 603-611, 2020 | 478 | 2020 |
| Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study PY Chia, SWX Ong, CJ Chiew, LW Ang, JM Chavatte, TM Mak, L Cui, ... Clinical microbiology and infection 28 (4), 612. e1-612. e7, 2022 | 411 | 2022 |
| Evaluation of the effectiveness of surveillance and containment measures for the first 100 patients with COVID-19 in Singapore—January 2–February 29, 2020 Y Ng MMWR. Morbidity and mortality weekly report 69, 2020 | 403 | 2020 |
Yee-Sin LeoProfessor of National Centre for Infectious DiseasesVerified email at ncid.sg
